EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Aldehyde Dehydrogenase 2 (ALDH2): A novel sorafenib target in hepatocellular carcinoma unraveled by the proteome-wide cellular thermal shift assay

Inês C Ferreira, Estefania Torrejón, Bernardo Abecasis, Bruno M Alexandre, Ricardo A Gomes, Chris Verslype, Jos van Pelt, Ana Barbas, Daniel Simão, Tiago M Bandeiras, Alessio Bortoluzzi, Sofia P Rebelo

SLAS Discovery · 2024

DOI: 10.1016/j.slasd.2024.100154 ↗

Kurz gefasst

Fachartikel in der Zeitschrift SLAS Discovery, 2024. Verfasst von Inês C Ferreira und 11 weiteren Autor:innen. Beteiligte Einrichtung: iBET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, 2781-901 Oeiras, Portugal. Hauptthemen laut MEDLINE: Sorafenib, Carcinoma, Hepatocellular, Liver Neoplasms, Aldehyde Dehydrogenase, Mitochondrial. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Instituto de Tecnologia Química e Biológica, Universidade Nova de Lisboa, Ministério da Ciência, Tecnologia e Ensino Superior, Fundação para a Ciência e a Tecnologia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sorafenib is a multikinase inhibitor indicated for first-line treatment of unresectable hepatocellular carcinoma. Despite its widespread use in the clinic, the existing knowledge of sorafenib mode-of-action remains incomplete. To build upon the current understanding, we used the Cellular Thermal Shift Assay (CETSA) coupled to Mass Spectrometry (CETSA-MS) to monitor compound binding to its target proteins in the cellular context on a proteome-wide scale. Among the potential sorafenib targets, we identified aldehyde dehydrogenase 2 (ALDH2), an enzyme that plays a major role in alcohol metabolism. We validated the interaction of sorafenib with ALDH2 by orthogonal methods using pure recombinant protein, proving that this interaction is not mediated by other cellular components. Moreover, we showed that sorafenib inhibits ALDH2 activity, supporting a functional role for this interaction. Finally, we were able to demonstrate that both ALDH2 protein expression and activity were reduced in sorafenib-resistant cells compared to the parental cell line. Overall, our study allowed the identification of ALDH2 as a novel sorafenib target and sheds light on its potential role in both hepatocellular carcinoma and sorafenib resistance condition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SorafenibCarcinoma, HepatocellularLiver NeoplasmsAldehyde Dehydrogenase, MitochondrialProteomeHumansCell Line, TumorProtein Kinase InhibitorsAntineoplastic AgentsDrug Resistance, NeoplasmProtein Binding

Stichwörter der Autor:innen

ALDH2CETSA-MSHCCSorafenibTarget validation

Substanzen

SorafenibAldehyde Dehydrogenase, MitochondrialALDH2 protein, humanProteomeProtein Kinase InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • iBET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, 2781-901 Oeiras, Portugal.
  • iBET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, 2781-901 Oeiras, Portugal; ITQB, ITQB-NOVA, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal.
  • Department of Gastroenterology and Hepatology, KU Leuven, Leuven, Belgium.
  • Department of Oncology, Laboratory of Clinical Digestive Oncology, KU, Leuven, Belgium.
  • iBET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, 2781-901 Oeiras, Portugal; Bayer Portugal, Carnaxide, Portugal.
  • iBET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, 2781-901 Oeiras, Portugal; ITQB, ITQB-NOVA, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal.…

Förderung

  • Instituto de Tecnologia Química e Biológica, Universidade Nova de Lisboa
  • Ministério da Ciência, Tecnologia e Ensino Superior
  • Fundação para a Ciência e a Tecnologia

Zitieren

APA

Ferreira, I. C., Torrejón, E., Abecasis, B., Alexandre, B. M., Gomes, R. A., Verslype, C., van Pelt, J., Barbas, A., Simão, D., Bandeiras, T. M., Bortoluzzi, A., & Rebelo, S. P. (2024). Aldehyde Dehydrogenase 2 (ALDH2): A novel sorafenib target in hepatocellular carcinoma unraveled by the proteome-wide cellular thermal shift assay. SLAS Discovery. https://doi.org/10.1016/j.slasd.2024.100154

Vancouver

Ferreira IC, Torrejón E, Abecasis B, Alexandre BM, Gomes RA, Verslype C, et al. Aldehyde Dehydrogenase 2 (ALDH2): A novel sorafenib target in hepatocellular carcinoma unraveled by the proteome-wide cellular thermal shift assay. SLAS Discovery. 2024. doi:10.1016/j.slasd.2024.100154

BibTeX
@article{Ferreira2024,
  author = {Ferreira, Inês C and Torrejón, Estefania and Abecasis, Bernardo and Alexandre, Bruno M and Gomes, Ricardo A and Verslype, Chris and van Pelt, Jos and Barbas, Ana and Simão, Daniel and Bandeiras, Tiago M and Bortoluzzi, Alessio and Rebelo, Sofia P},
  title = {Aldehyde Dehydrogenase 2 (ALDH2): A novel sorafenib target in hepatocellular carcinoma unraveled by the proteome-wide cellular thermal shift assay},
  journal = {SLAS Discovery},
  year = {2024},
  doi = {10.1016/j.slasd.2024.100154}
}
Kostenlos starten →